Prevention of Human Cytomegalovirus (HCMV) Mother-to-Fetus Transmission by Administration of Virus-Specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection.

Trial Profile

Prevention of Human Cytomegalovirus (HCMV) Mother-to-Fetus Transmission by Administration of Virus-Specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs Cytomegalovirus immune globulin (Primary)
  • Indications Cytomegalovirus infections; Pregnancy
  • Focus Therapeutic Use
  • Acronyms CHIP
  • Most Recent Events

    • 03 Apr 2014 Results published in the New England Journal of Medicine.
    • 07 Dec 2011 Actual patient number is 124 according to ClinicalTrials.gov.
    • 07 Dec 2011 Additional trial acronym (CHIP) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top